ProShare Advisors
CRBP icon

ProShare Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

ProShare Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-684
Closed -$40K – 2379
2021
Q1 		$40K Buy
684
+117
+21% +$7.69K ﹤0.01% 2236
2020
Q4 		$21K Sell
567
-177
-24% -$6.62K ﹤0.01% 2087
2020
Q3 		$40K Buy
744
+58
+8% +$10.5K ﹤0.01% 1606
2020
Q2 		$173K Buy
686
+263
+62% +$53.1K ﹤0.01% 1494
2020
Q1 		$67K Sell
423
-311
-42% -$52.6K ﹤0.01% 1105
2019
Q4 		$120K Sell
734
-75
-9% -$11.1K ﹤0.01% 1674
2019
Q3 		$118K Sell
809
-12
-1% -$2.09K ﹤0.01% 1531
2019
Q2 		$171K Sell
821
-87
-10% -$18.6K ﹤0.01% 1469
2019
Q1 		$189K Buy
908
+86
+10% +$19K ﹤0.01% 1486
2018
Q4 		$144K Sell
822
-159
-16% -$31.7K ﹤0.01% 1432
2018
Q3 		$222K Sell
981
-39
-4% -$6.3K ﹤0.01% 1537
2018
Q2 		$154K Sell
1,020
-46
-4% -$8.36K ﹤0.01% 1665
2018
Q1 		$195K Sell
1,066
-159
-13% -$35.7K ﹤0.01% 1558
2017
Q4 		$261K Buy
+1,225
New +$262K ﹤0.01% 1487

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

ProShare Advisors's CRBP Position: Q2 2021 in Review

ProShare Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 684 shares — an estimated $40K sold.

ProShare Advisors first reported a position in CRBP in Q4 2017 and held it in 14 quarters. The position peaked at $261K in Q4 2017. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

  • ProShare Advisors reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • ProShare Advisors sold 684 Corbus Pharmaceuticals shares in Q2 2021, an estimated $40K.
  • ProShare Advisors first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 14 quarters.
  • ProShare Advisors's Corbus Pharmaceuticals position peaked at $261K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.